Sign in
Should We Ever Consider Stopping Treatment for Neovascular AMD?
Rahul N. Khurana, MD, FASRS
Updates from the Field
2020
Episode 2: Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration with Dr. Brian Ballio
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
Category: Neovascular AMD